Les nouveaux antifongiques et leur straégie de recherche

Revue Francaise des Laboratoires

Volumn 2001, Issue 332, 2001, Pages 63-70

  Mallié, Michèle ^a   Bastide, Jean Marie ^a  

^a UNIV MONTPELLIER   (France)

Author keywords

Antifungal drugs; Benanomicins; Echinocandins; Nikkomycins; Pneumocandins; Pradimicins; Triazoles

Indexed keywords

EID: 0035314994     PISSN: 03389898     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0338-9898(01)80129-3     Document Type: Article

References (54)

1. Abruzzo G.K., Flattery A.M., Gill C.J., et al. Evaluation of the echinocandin antifungal MK-0991 (L-743-872): efficacies in mouse models of disseminated aspergillosis, candidiasis and cryptococcosis. Antimicrob. Agents. Chemother. 41:1997;2333-2338.
2. th Interscience Conference on Antimicrobial Agent and Chemotherapy, Toronto (September 17-20, 2000). 2000;932 American Society of Microbiology, Washington DC. Abstract.
3. th Intersciences Conference on Antimicrobial Agent and Chemotherapy, Toronto (September 17-20, 2000). 2000;2115 American Society of Microbiology, Washington DC. Abstract.
4. Barry A.L., Brown S.D. In vitro studies of two triazole antifungal agent (voriconazole UK-109 496 and fluconazole) against Candida species, Antimicrob. Agents Chemother. 40:1996;1948-1949.
5. Bartizal K., Gill C.J., Abruzzo G.K., et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (KL-743-872). Antimicrob. Agents Chemother. 41:1997;2326-2332.
6. Bryskier A. Antibiotiques, agents antibactériens et antifongiques. Ellipses Ed., 1999;. Paris.
7. Denning D.W. Echinocandins and pneumocandins - a new antifungal class with a novel mode of action. J. Antimicrobiol. Chemother. 40:1997;611-614.
8. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH565692 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:1998;2950-2956.
9. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109, 496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J. Clin. Microbiol. 36:1998;198-202.
10. Espinel-Ingroff A.V. Sch-56592 (Schering Plough). Curr Opinion Anti-Infective Invest. Drugs. 1:1999;377-384.
11. Galgiani J.N., Lewis M.L. In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptotoccus neoformans and other pathogenic yeasts, Antimicrob. Agents Chemother. 41:1997;180-183.
12. Georgopapadakou N.H., Walsh T.J. Antifungal agents chemotherapeutic targerts and immunologic strategies. Antimicrob. Agents Chemother. 40:1996;279-291.
13. Georgopapadakou N.H. BMS-207147 (Eisai Co Ltd). Curr. Opinion Anti-Infective Invest. Drugs. 1:1999;373-376.
14. Graybill J.R., Najvar L.K., Luther M.F., et al. Treatment of murine disseminated candidiasis with L-743872. Antimicrob. Agents Chemother. 41:1997;1775-1777.
15. Graybill J.R., Tollemar J., Torres-Rodriguez J.M., et al. Antifungal compounds: controversies, queries and conclusions. Med. Mycol. 38:2000;323-333. (Suppl. 1).
16. Grillot R., Noël T. Antifongiques et antifongigrammes. Option Bio. 224:1999;S1-16.
17. Hata K., Kimura J., Miki H., et al. In vitro and in vivo antifungal activities of ER 30346, a novel oral triazole with a broad antifungal spectrum. Antimicronb. Agents Chemother. 40:1996;2237-2242.
18. Hossain M.A., Maesaki S., Kakeya H., et al. Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans. Antimicrob. Agents Chemother. 42:1998;1722-1725.
19. th Interscience Conference on Antimicrobial Agent and Chemotheraphy, Toronto (September 17-20, 2000). 2000;1086 American Society of Microbiology, Washington DC. Abstract.
20. Ikeda F., Wakai Y., Matsumoto S., et al. Efficacy of FK 463, a new lipopeptide antifungal agent, in mouse models on disseminated candidiasis and aspergillosis. Antimicrob. Agents Chemother. 44:2000;614-618.
21. th Internscience Conference on Antimicrobial Agent and Chemotherapy, Toronto (September 17-20, 2000). 2000;1091 American Society of Microbiology, Washington DC. Abstract.
22. Keltin Y., Hitchcock C.A. Progress in the research for new triazole antifungal agents. Curr. Opin. Chem. Biol. 1:1997;176-182.
23. th Interscience Conference on Atimicrobial Agent and Chemotherapy, Toronto (September 17-20, 2000). 1686;American Society of Microbiology, Washington DC. Abstract.
24. Kurtz M.B. New Antifungal drug targert: a vision for the future. ASM News. 64:1998;31-39.
25. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins, 1 Drug solubilization and stabilization. J. Pharm. Sci. 85:1996;1017-1025.
26. Lortholary O., Tod M., Dupont B. Antifongiques, Encycl. Med. Chir. (Elsevier, Paris) Maladies Infectieuses. 1998;1-21. 8-004-M-10.
27. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto (September 17-20, 2000). 2000;1083 American Society of Microbiology, Washington DC. Abstract.
28. McGinnis M.R., Pasarell Sutton D.A.L., et al. In vitro activity of voriconzaole against selected fungi. Med. Mycol. 36:1998;239-242.
29. Oakley K.L., Moore C.B., Denning D.W. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus sp. Antimicrob. Agents Chemother. 41:1997;1124-1126.
30. Oki T., Konishi M., Tomatsu K., et al. Pradimicin, a novel class of potent antifungal antibiotics. J. Antibiot. 41:1988;1701-1704.
31. Otsubo T., Maesaki S., Hossain M.A., et al. In vitro and in vivo activities of NS-718, a new lipid nanopsphere incorporation amphotericin B, against Aspergillus fumigatus. Antimicrob. Agents Chemother. 40:1996;1577-1583.
32. Perfect J.R. Fungal virulence genes as targets for antifungal chemotherapy. Antimicrob. Agents Chemother. 40:1996;1577-1583.
33. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, (September 17-20, 2000). 2000;1083 American Society of Micrbiology, Washington DC. Abstract.
34. Petraitis V., Petratienes R., Groll A., et al. Antifungal efficacy of LY303366, a novel echinocandin B, in exprimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:1998;2898-2905.
35. Petratienes R., Petraitis V., Groll A., et al. Antifungal efficacy, safety, and single dose plasma pharmacokinetics of LY 303366, a novel echinocandin B, in experimental disseminated candidiasis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 43:1999;2148-2155.
36. th Interscience Conference on Antimicrobial Agent and Chemotherapy, Toronto (September 17-20, 2000). 2000;1104 American Society of Microbiology, Washington DC. Abstract.
37. Pfaller M.A., Messer S., Jones R.N. Activity of a new triazole, SCH 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida sp. and Saccharomyces cerevisieae. Antimicrob. Agents Chemother. 41:1997;233-235.
38. Pfaller M.A., Messer S.A., Coffman S. In vitro susceptibilities of clinical yeasts isolates to a new echinocandin derivative, LY 303366, and other antifungal agents. Antimicrob. Agents Chemother. 41:1997;763-766.
39. Pfaller M.A., Macro F., Messer S.A., et al. In vitro activity of two echocandin derivatives, LY 303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:1998;251-255.
40. Powles M.A., Liberator P., Anderson J., et al. Efficacy of MK-991 (L-743-872), a semisynthetic pneumocandin in murine models of Pneumocystis carinii. Antimicrob. Agents Chemother. 42:1998;1985-1989.
41. Prentice H.G., Hann I.M., Herbrecht R., et al. A randomized comparison of liposomal versus conventional amphotericine B for the traitment of pyrexia of unknown origin in neutropenic patients. Br. J. Haematol. 98:1997;711-718.
42. Radford S.A., Johnson E.M., Warnock D.W. In vitro studies of activities of voriconazole (UK-109 496), a new triazole antifungal agent, against emerging and less-common mold pathogens, Antimicrob. Agents Chemother. 41:1997;841-843.
43. Rhunke M.A., Schmidt-Westhausen A., Trautmann M. In vitro activities of voriconazole (UK-109 496) against fluconazole-susceptible and - resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother. 41:1997;575-577.
44. Sheehan D.J., Hitchcock C.A., Sibley C.M. Current and emerging azole antifungal agents. Clin. Microbiol. 12:1999;40-79.
45. Takeuchi T., Hara T., Naganawa T., et al. New antifungal antibiotics: benanomicins A and B from actinomycetes. J. Antibiot. 41:1988;807-811.
46. Traxler P., Gruner J., Auden J.A. Papulacandines, a new family of antibiotics with antifungal activity, I. Fermentation, isolation, chemical and biological characterization of papulacandins A, B, C, D and E. J. Antibiot. 30:1977;289-296.
47. Van de Velde V.J., Van Peer A.P., Heykants J.J., et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy. 16:1996;424-428.
48. Verweij P.E., De Pauw B.E., Meis J.F. Voriconazole (Pfizer Ltd). Curr. Opinion Anti-Infective Invest. Drugs. 1:1999;361-372.
49. Viviani M.A., De Marie S., Graybill J.R., et al. New approaches to antifungal chemotherapy. Med. Mycol. 36:1998;194-206. (Suppl. 1).
50. Walsh T.J., Finberg R.W., Arndt C., et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. New Engl. J. Med. 340:1999;764-771.
51. Walsh J.J., Viviani M.A., Arathoon E., et al. New targets and delivery systems for antifungal therapy. Med. Mycol. 38:2000;335-347. (Suppl. 1).
52. th Interscience Conference on Antimicrobial Agent and Chemotherapy, Toronto (September 17-20, 2000). 2000;930 American society of Microbiology, Washington DC. Abstract.
53. Yotsuji A., Shimizu K., Araki H., et al. T.8581, a new orally and parenterally active triazole antifungal agent, In vitro and in vivo evaluation. Antimicrob. Agents Chemother. 41:1997;30-34.
54. th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco (September 26-29, 1999). 1999;American Society for Microbiology, Washington DC. Abstract 1939.